Scottish Medicines Consortium (SMC)

In October 2014, Dymista^® was approved by the Scottish Medicines Consortium (SMC) for use within NHS Scotland.¹

Assessment based on a broad range of evidence

Members of the SMC committee consider a broad range of evidence when deciding which medicines should be approved for use by NHS Scotland. Decisions are made from a broad perspective by including wide mixture of backgrounds among committee members, from clinicians – most of whom have a direct role in patient care – to three volunteer public partners, who ensure the views of the Scottish public are represented.¹

SUMMARY OF RECOMMENDATIONS FOR DYMISTA^®1

Indication under review: for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

For patients in whom the combination of azelastine hydrochloride and fluticasone propionate nasal spray is an appropriate choice of therapy, Dymista^® provides the two ingredients in a single nasal spray.

Click here for the full SMC advice

References

Scottish Medicine Consortium (SMC). Available at
https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plus-fluticasone-propionate-dymista-abbreviatedsubmission-92113/ Last accessed: November 2023.

DYM-2023-0849 November 2023

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?

YES

Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW

Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.
Adverse reactions/events and device failures should also be reported to MAH at e-mail address: pv.uk@viatris.com.

This website is owned and managed by Viatris. For more information visit viatris.co.uk

This site is intended for UK healthcare professionals only. If you're a patient who has been prescribed Dymista^® (azelastine hydrochloride/fluticasone propionate), please click here.

Dymista^® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)